Drugs Containing Excipient (Inactive Ingredient) ALGELDRATE

Generic drugs containing ALGELDRATE excipient

Company	Ingredient	NDC	Excipient
Pfizer Laboratories Div Pfizer Inc	tick-borne encephalitis vaccine	0069-0297	ALGELDRATE
E Fougera & Co a division of Fougera Pharmaceuticals Inc	nystatin	0168-0054	ALGELDRATE
E Fougera & Co a division of Fougera Pharmaceuticals Inc	nystatin and triamcinolone acetonide	0168-0081	ALGELDRATE
Cosette Pharmaceuticals Inc	nystatin cream	0713-0678	ALGELDRATE
Rebel Distributors Corp	nystatin	21695-761	ALGELDRATE
A-S Medication Solutions	nystatin	50090-3772	ALGELDRATE

Algeldrate Market Dynamics, Financial Trajectory, Supply Chain, and Pharmaceutical IP Analysis

Last updated: August 22, 2026

Algeldrate, commonly identified as aluminum hydroxide or aluminum hydroxide dried gel, is a mature, low-cost pharmaceutical material with two distinct markets: an active pharmaceutical ingredient in antacids and phosphate binders, and a functional excipient or adjuvant component in selected formulations. Its commercial trajectory is stable rather than high growth. Volume demand is supported by over-the-counter antacid consumption, vaccine manufacturing, and generic oral medicines, while pricing is constrained by abundant mineral-based supply and limited differentiation.

The strongest commercial opportunities are in pharmaceutical-grade consistency, specialty particle engineering, vaccine-grade aluminum hydroxide, regulatory documentation, and reliable supply. Patent protection is generally weak. The principal barriers are manufacturing qualification, pharmacopoeial compliance, customer validation, and regulatory change-control requirements.

What is algeldrate and how is it used in pharmaceuticals?

Algeldrate is a hydrated aluminum oxide material generally represented as aluminum hydroxide, Al(OH)3. The substance is also known as aluminum hydroxide gel, hydrated alumina, dried aluminum hydroxide gel, and CAS Registry Number 21645-51-2.

Its pharmaceutical uses depend on grade and formulation:

Use	Commercial role	Typical formulation
Antacid	Active ingredient	Oral suspensions, chewable tablets, combination liquids
Phosphate binder	Active ingredient	Tablets, capsules, oral suspensions
Vaccine adjuvant	Immunological adjuvant	Injectable suspensions
Adsorbent	Functional excipient	Selected oral and biological formulations
Suspending or rheology aid	Formulation component	Liquid and semisolid systems
Processing aid	Manufacturing support	Selected pharmaceutical products

The distinction between algeldrate as an active ingredient and as an excipient matters commercially. Antacid and phosphate-binder products require active-ingredient controls and therapeutic labeling. Vaccine applications require tighter control of particle size, surface chemistry, adsorption capacity, sterility-related attributes, and batch consistency.

The U.S. Food and Drug Administration lists aluminum hydroxide in its Inactive Ingredient Database for certain approved drug products, but the material is also widely regulated as an active ingredient in over-the-counter antacids and prescription phosphate binders. FDA’s OTC Monograph M001 identifies aluminum hydroxide among permitted antacid active ingredients, subject to dosage and labeling conditions.[1]

How large is the algeldrate pharmaceutical market?

No major public company reports algeldrate revenue as a separate product category. Market research reports typically aggregate aluminum hydroxide into broader segments such as antacids, pharmaceutical excipients, vaccine adjuvants, inorganic chemicals, or specialty minerals.

The addressable market is best understood through three layers:

1. Finished antacid and phosphate-binder products.
2. Pharmaceutical-grade aluminum hydroxide used in those products.
3. Vaccine-grade aluminum hydroxide used as an adjuvant.

The raw material itself is a small fraction of the value of finished medicines. A conventional oral antacid may contain substantial quantities of aluminum hydroxide, but the material cost remains low relative to packaging, distribution, brand marketing, manufacturing, and regulatory compliance. Vaccine-grade material commands higher unit economics because of qualification requirements and tighter specifications, although total volumes are much lower than in antacid products.

Market-growth profile by end use

Segment	Demand outlook	Pricing power	Main growth driver
OTC antacids	Low to moderate	Low	Stable gastrointestinal self-care demand
Generic phosphate binders	Low to moderate	Low to medium	Chronic kidney disease prevalence and generic utilization
Vaccine adjuvants	Moderate	Medium to high	Immunization volumes and new vaccine production
Specialty excipient use	Moderate from a small base	Medium	Formulation development and supplier qualification
Industrial aluminum hydroxide	Moderate	Low	Construction, flame retardants, and chemicals

The overall pharmaceutical algeldrate market should therefore be viewed as mature in oral medicines and more attractive in controlled, higher-specification applications. The material does not have the growth profile of novel excipients, lipid nanoparticles, biologics stabilizers, or advanced drug-delivery systems.

What is driving algeldrate demand?

OTC antacid consumption

Aluminum hydroxide remains present in combination antacid products, often with magnesium hydroxide. The combination balances aluminum-related constipation with magnesium-related laxative effects. Products such as Maalox and generic aluminum hydroxide/magnesium hydroxide suspensions demonstrate the continuing role of the material in gastrointestinal products.[2]

Demand is supported by:

• A large installed base of generic and private-label products.
• Long-standing physician and consumer familiarity.
• Low production cost.
• Availability in liquids, tablets, and chewable dosage forms.
• Use in combination products containing simethicone or alginic acid.

The main constraint is therapeutic substitution. Proton-pump inhibitors, H2-receptor antagonists, alginates, and other gastrointestinal products compete with traditional antacids. Antacids remain relevant for rapid, short-duration symptom relief, but their market is mature.

Chronic kidney disease and phosphate binding

Aluminum hydroxide can bind dietary phosphate in the gastrointestinal tract. Its use as a phosphate binder has declined in many markets because long-term aluminum exposure raises toxicity concerns, particularly in patients with renal impairment. Calcium-based binders, sevelamer, lanthanum carbonate, ferric citrate, and sucroferric oxyhydroxide compete in this category.[3]

This creates a mixed demand profile. Rising chronic kidney disease prevalence expands the underlying phosphate-binder market, but algeldrate captures only a limited share of that growth because clinical practice has moved toward non-aluminum alternatives for long-term treatment.

Vaccine adjuvant production

Aluminum hydroxide is one of the established aluminum adjuvants used in vaccines. Its market value is higher than that of standard oral pharmaceutical material because manufacturers must control morphology, surface charge, adsorption behavior, microbial quality, and batch reproducibility.

The commercial opportunity is linked to:

• Expanded routine immunization programs.
• Growth in emerging-market vaccine production.
• New protein-subunit and recombinant vaccines.
• Contract manufacturing and technology transfer.
• Demand for validated, prequalified adjuvant supply.

Vaccine adjuvant demand is less exposed to consumer antacid substitution, but it is more dependent on a small number of qualified suppliers and customer-specific manufacturing processes.

What are the main algeldrate suppliers and competitive dynamics?

The supply chain includes upstream alumina and aluminum chemical producers, specialty pharmaceutical-material manufacturers, excipient distributors, and vertically integrated vaccine-adjuvant suppliers.

Competition is based less on chemical novelty than on:

• Pharmacopoeial compliance.
• Particle-size distribution.
• Surface area and pore structure.
• Water content and hydration state.
• Trace metals and elemental impurities.
• Microbial and endotoxin control.
• Batch-to-batch adsorption performance.
• Documentation, audit readiness, and change-control discipline.
• Manufacturing-site redundancy.

Generic oral grades are vulnerable to price competition because multiple chemical manufacturers can produce aluminum hydroxide materials. Vaccine-grade products have higher switching costs. A customer must often repeat compatibility, adsorption, stability, and process-validation work before changing suppliers.

Large chemical companies may supply pharmaceutical-grade aluminum hydroxide directly or through specialist distributors. Smaller excipient suppliers compete through regional inventory, technical service, and documentation rather than scale. Contract manufacturers and vaccine producers can also maintain internal formulation know-how that makes the adjuvant specification customer-specific.

What formulations are protected by algeldrate patents?

Algeldrate has no meaningful composition-of-matter patent estate because aluminum hydroxide is an old inorganic compound. Commercial protection, where it exists, is more likely to involve:

• Specific antacid combinations.
• Particle-size or morphology-controlled materials.
• Vaccine-adjuvant compositions.
• Adsorption or delivery systems.
• Controlled-release formulations.
• Manufacturing processes producing defined surface properties.
• Combination products containing algeldrate with magnesium hydroxide, simethicone, alginic acid, or other actives.

Most historical patents covering basic aluminum hydroxide preparations have expired. Patent rights may still arise around a particular formulation or manufacturing process, but those rights generally protect the product architecture rather than algeldrate itself.

Patent-strength assessment

Patent category	Current strength	Commercial relevance
Aluminum hydroxide composition	Very low	Basic compound is long established
Standard antacid formulation	Very low to low	Most claims are expired or easily designed around
Combination antacid	Low to medium	Depends on active combination and delivery format
Vaccine adjuvant composition	Medium	Process and formulation claims may remain relevant
Particle-engineered algeldrate	Medium	Protection depends on measurable structural limitations
Manufacturing process	Medium	Qualification and process know-how may exceed patent value
Novel delivery system	Medium to high	Relevant only where algeldrate has a defined technical function

What is the FDA regulatory status of algeldrate?

Algeldrate has different regulatory treatment depending on its use.

For antacids, aluminum hydroxide is an OTC active ingredient under FDA’s antacid monograph framework. Products must comply with permitted active ingredients, dosage ranges, warnings, directions, and labeling requirements.[1]

For prescription or abbreviated new drug applications, aluminum hydroxide may appear as an active ingredient or inactive ingredient depending on the product’s intended function. FDA’s Inactive Ingredient Database is relevant to excipient precedent, but inclusion does not eliminate the need to demonstrate suitability for a specific route, dose, dosage form, and formulation.[4]

For vaccines, aluminum hydroxide is regulated as part of the finished biological product. FDA evaluates the adjuvant within the product’s chemistry, manufacturing, and controls package. A vaccine manufacturer cannot generally treat a change in adjuvant source as a routine procurement substitution. The change may require comparability work, process validation, stability data, and regulatory approval.

Key quality attributes

Pharmaceutical buyers typically evaluate:

• Identification and assay.
• Aluminum content.
• Water content and loss on drying.
• pH and alkalinity.
• Particle-size distribution.
• Surface area.
• Sedimentation and redispersibility.
• Elemental impurities.
• Microbial limits.
• Bacterial endotoxins for injectable applications.
• Adsorption capacity for vaccine use.

The United States Pharmacopeia and European Pharmacopoeia provide compendial frameworks for aluminum hydroxide and related materials.[5][6]

When does algeldrate lose exclusivity?

Algeldrate has no practical remaining exclusivity period as a substance. It is a legacy material with extensive generic use and historical regulatory precedent.

The relevant exclusivity questions concern finished products:

• OTC monograph products generally do not receive innovator-style patent exclusivity for the established active ingredient.
• Generic prescription products may face patents listed for formulation, method of use, or device features.
• Vaccine products may have product-specific patents and regulatory exclusivities, but those rights attach to the vaccine or adjuvant system, not necessarily to aluminum hydroxide itself.
• Supplier manufacturing know-how may remain confidential after patents expire.

The commercial risk is therefore rarely a direct algeldrate patent challenge. It is more often a formulation substitution issue, a manufacturing change-control issue, or a customer qualification barrier.

Which companies are challenging algeldrate products?

There is no identifiable industry-wide Paragraph IV campaign directed at algeldrate as an excipient. Paragraph IV litigation would generally target a branded finished drug with Orange Book-listed patents, not the underlying commodity excipient.

For aluminum hydroxide antacids, competition usually occurs through:

• ANDA launches for equivalent dosage forms.
• Private-label substitution.
• OTC monograph compliance.
• Price competition among contract manufacturers.
• Reformulation around inactive ingredients or packaging.
• Retail-channel competition.

Orange Book relevance is product-specific. An aluminum hydroxide-containing prescription product could have listed patents, but the presence of algeldrate does not itself create an Orange Book patent barrier.[7]

What manufacturing and IP barriers affect algeldrate supply?

Manufacturing barriers are stronger than patent barriers.

Oral-grade material

Standard oral-grade production is relatively accessible. Key inputs include alumina hydrate, aluminum salts, purified water, and controlled precipitation or gelation processes. The product’s commercial quality depends on washing, drying, milling, hydration control, and contamination management.

The principal risks are:

• Variable particle morphology.
• Inconsistent suspension behavior.
• Residual process chemicals.
• Elemental impurities.
• Supply interruption at the mineral or chemical-input stage.
• Long customer requalification cycles.

Vaccine-grade material

Vaccine-grade supply is substantially more difficult. The buyer is purchasing a validated material with defined biological and physicochemical performance, not simply aluminum hydroxide by chemical identity.

Barriers include:

• Dedicated or tightly controlled production areas.
• Higher microbial and endotoxin controls.
• Defined particle morphology.
• Adsorption consistency.
• Sterilization compatibility.
• Long-term stability data.
• Regulatory change notification.
• Customer-specific process qualification.

For vaccine manufacturers, supplier reliability and regulatory history can outweigh modest price differences. This creates a defensible position for qualified producers even when the underlying chemistry is off-patent.

How does algeldrate compare with competing excipients and antacid ingredients?

Material	Primary role	Competitive position
Magnesium hydroxide	Antacid and laxative	Common combination partner; low cost
Calcium carbonate	Antacid and calcium supplement	Strong OTC competitor; high availability
Sodium bicarbonate	Rapid antacid	Low-cost but limited by sodium and systemic effects
Sevelamer	Non-aluminum phosphate binder	Higher-value chronic kidney disease alternative
Lanthanum carbonate	Phosphate binder	Branded and generic competition
Ferric citrate	Phosphate binder and iron source	Competes in renal-care products
Sucroferric oxyhydroxide	Phosphate binder	Specialty alternative with differentiated dosing
Aluminum phosphate	Antacid	Alternative aluminum-based material
Aluminum hydroxide adjuvant	Vaccine adjuvant	Competes with aluminum phosphate, alum mixtures, and non-aluminum adjuvants

Algeldrate’s cost advantage is strongest in mature oral products. Its relative position is weaker where clinicians or regulators prioritize avoidance of aluminum exposure, reduced pill burden, or differentiated clinical performance.

What is the financial trajectory for algeldrate suppliers?

The financial trajectory is likely to be stable with modest nominal growth, but the mix matters.

Base-case trajectory

• Volume growth: low single digits in oral pharmaceutical applications.
• Pricing: limited in commodity oral grades.
• Margin: higher for vaccine-grade and validated specialty material.
• Capital intensity: moderate for standard production and higher for injectable-grade controls.
• Customer concentration: potentially high in vaccine-grade supply.
• Working capital: affected by regulatory inventory, shelf life, and regional stock requirements.

Revenue growth is more likely to come from geographic expansion, contract manufacturing, and qualification of higher-grade products than from a sharp increase in algeldrate consumption per medicine.

Upside factors

• Growth in vaccine manufacturing capacity.
• New protein-based vaccines requiring aluminum adjuvants.
• Outsourcing of pharmaceutical-grade excipient production.
• Supply disruption at incumbent manufacturers.
• Premium pricing for low-bioburden or high-consistency grades.
• Expansion in emerging markets where OTC antacids remain widely used.

Downside factors

• Substitution by non-aluminum phosphate binders.
• Declining use of traditional antacids.
• Environmental and energy costs affecting aluminum chemical production.
• Customer consolidation and purchasing pressure.
• New impurity or elemental-metal requirements.
• Qualification delays for new suppliers.
• Loss of vaccine programs or changes in adjuvant technology.

What is the investment and licensing outlook for algeldrate?

Algeldrate is unlikely to support a standalone high-growth licensing thesis. Licensing value is more plausible in:

• Proprietary vaccine-adjuvant platforms.
• Surface-modified aluminum hydroxide.
• Controlled adsorption systems.
• Combination delivery technologies.
• Manufacturing processes that improve consistency or reduce impurities.
• Regional supply agreements with pharmaceutical manufacturers.

A conventional algeldrate supply agreement is more likely to involve quality obligations, minimum purchase volumes, price-adjustment mechanisms, audit rights, and change-control provisions than royalty-bearing patent licenses.

For investors, the key diligence questions are supplier qualification status, customer concentration, vaccine exposure, capacity utilization, input-cost sensitivity, and the proportion of revenue generated by pharmaceutical versus industrial grades.

Key Takeaways

• Algeldrate is a mature aluminum hydroxide material with limited standalone patent value.
• Its largest pharmaceutical roles are antacids, phosphate binders, and vaccine adjuvants.
• Oral-grade demand is stable but price-sensitive.
• Vaccine-grade material has stronger margins and higher switching costs.
• The main competitive barriers are quality systems, regulatory documentation, process consistency, and customer qualification.
• Long-term phosphate-binder demand is growing, but algeldrate faces substitution from non-aluminum products.
• FDA Orange Book and Paragraph IV activity is product-specific, not directed at algeldrate as a substance.
• Public company filings do not generally disclose algeldrate revenue separately, so financial analysis must rely on end-use exposure and supplier mix.
• The most attractive commercial segment is validated, high-specification aluminum hydroxide for vaccines and specialty formulations.

FAQs

Is algeldrate the same as aluminum hydroxide?

Algeldrate is a pharmaceutical name used for hydrated aluminum hydroxide materials. Commercial specifications can differ by hydration state, morphology, particle size, and manufacturing process.

Is algeldrate still used in phosphate binders?

Yes, but its long-term use is constrained by aluminum accumulation concerns. Non-aluminum phosphate binders have captured substantial clinical and commercial demand.

Does algeldrate have active pharmaceutical patents?

The basic aluminum hydroxide compound does not have meaningful active composition patents. Protection may apply to specific formulations, adjuvant systems, particle structures, or manufacturing processes.

Is vaccine-grade algeldrate interchangeable between suppliers?

Usually not without qualification. Vaccine manufacturers must assess physicochemical comparability, adsorption performance, process compatibility, stability, and regulatory implications.

Is algeldrate a high-growth pharmaceutical excipient?

No. Standard oral-grade algeldrate is a mature material. Higher growth and margin potential exist in vaccine-grade and specialty, tightly controlled applications.

References

1. U.S. Food and Drug Administration. (2023). Antacid products for over-the-counter human use: Monograph M001. FDA.

2. Kenvue Inc. (2023). Maalox consumer product information and active ingredients. Kenvue.

3. Kidney Disease: Improving Global Outcomes. (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder. Kidney International Supplements, 7(1), 1-59.

4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Aluminum hydroxide. USP.

6. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia: Aluminum hydroxide. EDQM.

7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.